1. @ANDREW HESSEL JULY 31 02010 a drug company for everyone PINK ARMY COOPERATIVE

2. http://ilovebacteria.com/Images/bacterialcell.jpg http://i.dell.com/images/global/products/314x314/desktop-studio-mini-left-314.jpg

5. andrew hessel

7. COMPILE DESIGN design/build/test cycle EXECUTE TEST applications

8. David Appleyard

13. CANCER

16. CANCER R&D IS

18. Evolutionary distance ~ 4 billion years two completely different species, far removed, and bacteria are clonal

19. many chemical compounds have antimicrobial activity without seriously harming human cells

21. Evolutionary distance max: patient’s age cancer cells are same species, only recently diverged, and every divergence is unique, cells continue to degrade over time (mixed)

23. photo by billy hunt

25. christa slotboom

26. TARGETING FAST GROWING CELLS IS SO 1950 there are plenty of normal cells that grow fast too, making treatments needlessly harsh ONE-SIZE-FITS-ALL DRUGMAKING IS ILLOGICAL each person’s DNA is different, their mutations are different, cancers are of mixed cell types CANCER RESEARCHERS DON’T MAKE DRUGS drug companies make drugs A LOT OF RESEARCH ISN’T USEFUL there appears to be a near-infinite number of paths to cancer CHANGE IS HARD cancer is industry with tremendous inertia

27. THE IDEAL THERAPEUTIC specific to the cancer gentle effective made quickly inexpensive

28. http://www.nature.com/horizon/chemicalspace/background/images/odyssey-f1.jpg

29. Scientists new drug X shareholders Lawyers MANUFACTURERS clinical trials Economists physicians Insurance companies geneticists

31. system is inherently limited requires blockbusters unable to accelerate

32. RISK vs BENEFIT ( n >1) STATISTICAL ANALYSIS OF POPULATIONS requires large markets failure is expensive political slow

33. RISK vs BENEFIT ( n =1) no statistics – just direct observations risk benefit analysis always an individual decision ?

34. isolate and analyze design build test failures provide and evaluate SYNTHETIC BIOLOGY BIOFAB results COOPERATIVE data sharing

37. aims to bring together researchers, developers, cancer sufferers and supporters in a self-funded, open-source therapeutic venture

38. goal: not a new drug, but a completely new way of making drugs one that can accelerate and improve over time

39. a significant step towards faster, better, cheaper cancer drugs + =

40. diagnostics today, treatments tomorrow

41. pinkarmy.org join us